Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Public ClinicalTrials.gov record NCT06107426. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global Real-World Evidence Study on the Long-term Effectiveness of ABBV-951 in Advanced Parkinson´s Disease in Routine Clinical Practice (ROSSINI: Real-world Outcomes With continuouS Subcutaneous Levodopa INfusIon)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. The purpose of this study is to evaluate how effective ABBV-951 is in treating adult participants with advanced PD in real world setting. ABBV-951 (foslevodopa/foscarbidopa) is an approved drug for the treatment of Parkinson's Disease. The main ROSSINI study will have approximately 450 adult participants with PD (300 participants new to ABBV-951, up to 150 participants transitioning from open-label extension study) will be enrolled across approximately 60 sites. Decision to treat with ABBV-951 (or continue the treatment in Cohort B) will be made by the doctor prior to any decision to approach the participant to participate in this study. There will be a sub-study that will enroll 40 naïve participants who initiated Foslevodopa/Foscarbidopa treatment for the first time (Cohort A of the ROSSINI parent study only) from 6 to 15 centers in the United States, Germany and Spain. All participants will receive subcutaneous infusion of ABBV-951 for approximately 3 years. Participants will attend regular clinic visits during the course of the study. The effect of the treatment will be checked by medical assessments, and completing questionnaires.
Study identification
- NCT ID
- NCT06107426
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 427 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2024 (Actual)
- Primary completion
- May 2029 (Estimated)
- Completion
- May 2029 (Estimated)
- Last update posted
- Apr 27, 2026
2024 – 2029
United States locations
- U.S. sites
- 27
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham - Main /ID# 253477 | Birmingham | Alabama | 35233 | — |
| Banner Sun Health Research Institute /ID# 253461 | Sun City | Arizona | 85351 | — |
| Parkinson's Research Centers of America - Palo Alto /ID# 264703 | Palo Alto | California | 94301-2011 | — |
| Georgetown University Hospital /ID# 259381 | Washington D.C. | District of Columbia | 20007 | — |
| Parkinson's Disease and Movement Disorders Center of Boca Raton /ID# 253465 | Boca Raton | Florida | 33486 | — |
| University of Florida College of Medicine /ID# 259383 | Gainesville | Florida | 32610 | — |
| University of Miami /ID# 259396 | Miami | Florida | 33138 | — |
| N1 Research, LLC /ID# 264221 | Orlando | Florida | 32825-3769 | — |
| University of South Florida- Neuroscience Institute /ID# 253470 | Tampa | Florida | 33613 | — |
| Northwestern Medicine Primary And Specialty Care Lavin Family Pavilion /ID# 266977 | Chicago | Illinois | 60611 | — |
| Ochsner Medical Center - Jefferson Highway /ID# 269764 | New Orleans | Louisiana | 70121 | — |
| Boston Medical Center Health System /ID# 269765 | Brighton | Massachusetts | 02135 | — |
| University of Minnesota - Minneapolis /ID# 268121 | Minneapolis | Minnesota | 55455-0341 | — |
| Kansas City VA Medical Center /ID# 253466 | Kansas City | Missouri | 64128 | — |
| Cleveland Clinic Lou Ruvo Cent /ID# 259390 | Las Vegas | Nevada | 89106-0100 | — |
| David L. Kreitzman, MD, PC /ID# 259397 | Commack | New York | 11725-6021 | — |
| Northwell Health /ID# 253469 | Lake Success | New York | 11042 | — |
| Novant Health Neurology and Sleep /ID# 259391 | Charlotte | North Carolina | 28207-1100 | — |
| Atrium Health Wake Forest Baptist Medical Center /ID# 259387 | Winston-Salem | North Carolina | 27157 | — |
| NeuroCare Center /ID# 259392 | Canton | Ohio | 44718-2531 | — |
| The Movement Disorder Clinic of Oklahoma /ID# 253463 | Tulsa | Oklahoma | 74136-6378 | — |
| Vanderbilt University Medical Center /ID# 253474 | Nashville | Tennessee | 37232-0011 | — |
| Texas Movement Disorder Specialists /ID# 253473 | Georgetown | Texas | 78628-4126 | — |
| Univ Texas HSC San Antonio /ID# 259394 | San Antonio | Texas | 78229-3901 | — |
| University of Utah /ID# 253471 | Salt Lake City | Utah | 84112-5500 | — |
| Evergreenhealth Medical Center /ID# 268120 | Kirkland | Washington | 98034 | — |
| Inland Northwest Research /ID# 253460 | Spokane | Washington | 99202-1342 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06107426, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06107426 live on ClinicalTrials.gov.